New combo drug shows promise for fatty liver in diabetes patients
NCT ID NCT07274644
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 24 times
Summary
This study compares a combination diabetes drug (iGlarLixi) to insulin alone to see which better reduces liver fat in people with type 2 diabetes and fatty liver disease. About 36 participants will take the assigned treatment for 12 weeks. The goal is to find a better way to manage both blood sugar and liver health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210008, China
Conditions
Explore the condition pages connected to this study.